AU2016291228B2 - Compositions and methods for treating lung diseases and lung injury - Google Patents

Compositions and methods for treating lung diseases and lung injury Download PDF

Info

Publication number
AU2016291228B2
AU2016291228B2 AU2016291228A AU2016291228A AU2016291228B2 AU 2016291228 B2 AU2016291228 B2 AU 2016291228B2 AU 2016291228 A AU2016291228 A AU 2016291228A AU 2016291228 A AU2016291228 A AU 2016291228A AU 2016291228 B2 AU2016291228 B2 AU 2016291228B2
Authority
AU
Australia
Prior art keywords
mol
composition
lipid
rnai
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016291228A
Other languages
English (en)
Other versions
AU2016291228A1 (en
Inventor
Kuan-Ju CHEN
Keith DIPETRILLO
Franziska LEIFER
Vladimir Malinin
Walter Perkins
Jimin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Inc
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of AU2016291228A1 publication Critical patent/AU2016291228A1/en
Application granted granted Critical
Publication of AU2016291228B2 publication Critical patent/AU2016291228B2/en
Priority to AU2020203367A priority Critical patent/AU2020203367A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2016291228A 2015-07-09 2016-07-11 Compositions and methods for treating lung diseases and lung injury Active AU2016291228B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020203367A AU2020203367A1 (en) 2015-07-09 2020-05-22 Compositions and methods for treating lung diseases and lung injury

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190583P 2015-07-09 2015-07-09
US62/190,583 2015-07-09
PCT/US2016/041776 WO2017008076A1 (en) 2015-07-09 2016-07-11 Compositions and methods for treating lung diseases and lung injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203367A Division AU2020203367A1 (en) 2015-07-09 2020-05-22 Compositions and methods for treating lung diseases and lung injury

Publications (2)

Publication Number Publication Date
AU2016291228A1 AU2016291228A1 (en) 2017-12-07
AU2016291228B2 true AU2016291228B2 (en) 2020-04-09

Family

ID=57686097

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016291228A Active AU2016291228B2 (en) 2015-07-09 2016-07-11 Compositions and methods for treating lung diseases and lung injury
AU2020203367A Abandoned AU2020203367A1 (en) 2015-07-09 2020-05-22 Compositions and methods for treating lung diseases and lung injury

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020203367A Abandoned AU2020203367A1 (en) 2015-07-09 2020-05-22 Compositions and methods for treating lung diseases and lung injury

Country Status (7)

Country Link
US (1) US20180200186A1 (enExample)
EP (1) EP3319976B1 (enExample)
JP (1) JP6884714B2 (enExample)
AU (2) AU2016291228B2 (enExample)
CA (1) CA2989884A1 (enExample)
ES (1) ES2898340T3 (enExample)
WO (1) WO2017008076A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5324223B2 (ja) 2005-12-08 2013-10-23 トランセイブ， インク． 肺感染症を治療する抗感染薬の脂質ベースの組成物及びその使用法
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
MX2015006681A (es) 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
SI3060041T1 (sl) 2013-10-25 2021-04-30 Insmed Incorporated Spojine prostaciklina
SMT202000516T1 (it) 2014-05-15 2020-11-10 Insmed Inc Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
WO2019213398A1 (en) 2018-05-02 2019-11-07 Insmed Incorporated Methods for the manufacture of liposomal drug formulations
JP2021532098A (ja) * 2018-07-19 2021-11-25 インペル ニューロファーマ インコーポレイテッド パーキンソン病の治療のためのレボドパおよびドーパデカルボキシラーゼ阻害剤の呼吸管路送達
EP3846822A4 (en) * 2018-09-04 2022-07-06 The Board Of Regents Of The University Of Texas System COMPOSITIONS AND METHODS FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS
CN113166783B (zh) 2018-10-09 2024-10-11 不列颠哥伦比亚大学 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
CN109432047B (zh) * 2018-10-29 2021-07-20 中国药科大学 一种逆转肺纤维化纳米制剂及其制备方法
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
CN115297850A (zh) * 2019-12-05 2022-11-04 得克萨斯州大学系统董事会 用于肝纤维化和其他与纤维化相关的疾病的基于外排体的治疗
GB2613457B (en) 2020-04-09 2023-12-06 Verve Therapeutics Inc Base editing of angptl3 and methods of using same for treatment of disease
CN115768438A (zh) * 2020-07-10 2023-03-07 盖纳万科学有限公司 用于向肺递送治疗剂的脂质纳米颗粒
EP4213882A4 (en) 2020-09-15 2025-02-26 Verve Therapeutics, Inc. LIPID FORMULATIONS FOR GENE EDITING
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines
WO2022204219A1 (en) 2021-03-22 2022-09-29 Recode Therapeutics, Inc. Compositions and methods for targeted delivery to cells
CN113058042B (zh) * 2021-04-01 2023-06-30 易慧生物技术(上海)有限公司 一种可鼻喷的稳定递载rna分子的脂质纳米颗粒制备方法
CN115245559B (zh) * 2021-04-25 2026-05-01 上海萨美细胞技术有限公司 一种用于治疗肺损伤的药物
EP4352240A4 (en) * 2021-06-09 2025-07-09 Recode Therapeutics Inc POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS AND METHODS OF USE THEREOF
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
WO2023019192A1 (en) * 2021-08-11 2023-02-16 Board Of Regents, The University Of Texas System Dry liposome formulations and related methods thereof
PL249473B1 (pl) * 2021-08-14 2026-04-27 Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie jako nośnika leku oraz w terapii genowej i sposób ładowania liposomu emetyną
EP4226949A1 (en) * 2022-02-14 2023-08-16 Pantherna Therapeutics GmbH Preparation for use in a method for the treatment and/or prevention of a disease
WO2024242216A1 (ko) * 2023-05-23 2024-11-28 주식회사 케이더블유바이오 대식세포 표적화 리포좀 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2199298A1 (en) * 2004-11-17 2010-06-23 Protiva Biotherapeutics Inc. Sirna silencing of Apolipoprotein B
WO2011108955A1 (en) * 2010-03-03 2011-09-09 Universidade De Coimbra Multi -targeting system comprising a nanocarrier, nucleic acid(s) and non-nucleic acid based drug(s)
US20140308304A1 (en) * 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2536071A1 (en) * 2003-08-20 2005-03-03 Locomogene, Inc. Methods for detecting regulatory effect on synoviolin activity
JP5777519B2 (ja) * 2008-10-09 2015-09-09 テクミラ ファーマシューティカルズ コーポレイション 改良されたアミノ脂質および核酸の送達方法
US9944671B2 (en) * 2010-06-02 2018-04-17 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
US20150246137A1 (en) * 2012-09-27 2015-09-03 The University Of North Carolina At Chapel Hill Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2199298A1 (en) * 2004-11-17 2010-06-23 Protiva Biotherapeutics Inc. Sirna silencing of Apolipoprotein B
WO2011108955A1 (en) * 2010-03-03 2011-09-09 Universidade De Coimbra Multi -targeting system comprising a nanocarrier, nucleic acid(s) and non-nucleic acid based drug(s)
US20140308304A1 (en) * 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents

Also Published As

Publication number Publication date
EP3319976A1 (en) 2018-05-16
US20180200186A1 (en) 2018-07-19
CA2989884A1 (en) 2017-01-12
JP6884714B2 (ja) 2021-06-09
AU2016291228A1 (en) 2017-12-07
JP2018519818A (ja) 2018-07-26
EP3319976A4 (en) 2019-03-20
EP3319976B1 (en) 2021-09-01
WO2017008076A1 (en) 2017-01-12
AU2020203367A1 (en) 2020-06-11
ES2898340T3 (es) 2022-03-07

Similar Documents

Publication Publication Date Title
EP3319976B1 (en) Compositions and methods for treating lung diseases and lung injury
JP6990176B2 (ja) メッセンジャーリボ核酸薬物の治療投与のための方法
JP6023126B2 (ja) 標的遺伝子の発現を抑制する組成物
US20070293449A1 (en) Compositions and methods for delivery of double-stranded rna
US20080076701A1 (en) Dicer substrate rna peptide conjugates and methods for rna therapeutics
JP2024541993A (ja) Ｒｎａコンストラクト及びその使用
JP2008504827A (ja) 免疫賦活性ｓｉＲＮＡ分子およびその使用方法
CN118319880B (zh) 靶向肺部高效递送核酸的脂质纳米颗粒、吸入式制剂及应用
EP4041400B1 (en) Messenger rnas encoding sting and il-12 and use in the treatment of cancer
CN118766874B (zh) 一种吸入式制剂、迭代优化流程及其应用
KR102931885B1 (ko) 대식세포 유래 소포로 코팅된 지질 나노입자 및 이의 제조 방법
JP2025533111A (ja) Ｒｎａコンストラクト及びその使用
WO2024026257A2 (en) Engineered polynucleotides for cell selective expression
WO2023019310A1 (en) Lipid nanoparticle formulations
You et al. p65 siRNA-loaded buformin/DNA nanoprisms alleviate acute lung injury through inhibiting NLRP3-mediated pyroptosis
US20220257614A1 (en) Use of 12-lipoxygenase inhibitors in the treatment of covid-19
WO2023240225A1 (en) Constitutively active polymeric sting mimics for antitumor immunity
JP2023039115A (ja) 物質送達キャリア及び組成物
JP5872898B2 (ja) 標的遺伝子の発現を抑制する組成物
WO2012098692A1 (ja) 標的遺伝子の発現を抑制する組成物
WO2025149492A1 (en) Rna encoding an immune inhibitory il-1 family member
HK1126785B (en) Modified sirna molecules and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)